ALPX S-1/Aamended IPO prospectus

Executive Summary

Alopexx develops vaccines and antibodies to prevent infections in older adults and hospital patients; it has no approved products or revenue and ultimately seeks product sales and licensing income. Its priority is proving that targeting PNAG, a substance shared by many microbes, can complement pneumococcal vaccines and prevent intensive-care infections. Losses have narrowed, but largely because stock-based compensation declined—not because commercialization is closer. The unpriced IPO seeks $30M–$36M at an implied $83.0M–$99.6M market capitalization, giving buyers 36% ownership; investors are funding clinical proof, with further financing required before pivotal trials.

Business Model and Growth Drivers

Alopexx’s opportunity rests on broad protection from one microbial target rather than separate treatments for individual pathogens. Its AV0328 vaccine completed a 16-person Phase 1 study with no serious adverse events; participants’ antibodies killed tested PNAG-positive organisms in laboratory assays, but human protection remains unproven. Management plans a dose-and-schedule study in ≈100 adults over 50 after the IPO. F598 supplies antibodies directly: a single infusion maintained serum levels for two to three months. Its safety studies were encouraging, but a 25-person tuberculosis study did not meet its efficacy endpoint. The next test is infection prevention in intensive-care units, alongside—not instead of—antibiotics.

Alopexx and eight Assistance Publique—Hôpitaux de Paris hospitals have agreed to a 1,600-patient F598 study. Management anticipates starting in Q1 2027, completing it ≈18 months later, and spending ≈$4M. Positive results would still require a confirmatory registration trial. Exploratory neuroinflammation candidates AB0411 and AV0407 are also slated to begin development in Q1 2027, although anti-infectives remain the priority.

Management projects potential annual sales above $2B for AV0328 and $3B for F598; these are scenarios, not orders. The latter assumes 60% penetration of U.S. intensive-care admissions. Established vaccine competitors and reimbursement decisions could sharply limit uptake.

Execution is outsourced. Glycosyn supplies a critical vaccine component, Lonza develops and manufactures F598, and Bharat Biopharm supports vaccine manufacturing. Bharat holds licensed rights in specified lower-income markets. Brigham and Women’s Hospital licenses require $0.165M annually, potential milestones totaling $4.18M, and royalties, reducing eventual economics.

The Offering

• Size and valuation: 3,000,000 new shares at $10.00–$12.00 imply $30M–$36M gross proceeds, $83.0M–$99.6M market capitalization on 8,299,557 post-offering shares, and 36% ownership for IPO buyers. Including outstanding options and representative warrants gives 9,868,945 fully diluted shares, implying $98.7M–$118M and a 30% buyer stake. Revenue and earnings multiples are not meaningful.
• Execution: The offering remains unpriced. ThinkEquity leads underwriting and may buy 450,000 additional shares within 45 days. Closing depends on NYSE American approving “ALPX.”
• Proceeds: The company—not selling shareholders—receives estimated net proceeds of ≈$30.1M at $11.00, or ≈$34.7M with the option. Planned allocations are $6M to AV0328, $9M to the antibody program, $4M to neuroinflammation, and the remainder to general purposes. Funding covers at least 12 months of current plans, not pivotal development.
• Dilution: Each $11.00 share would be backed by $2.95 of net tangible assets after the IPO, an $8.05 gap. Existing holders paid $1.36 per share on average.
• Capitalization bridge: Conversion exchanges $1.25M note principal plus $0.362M accrued interest for 195,425 shares. Offering cash then adds ≈$30.1M, while $0.883M of previously deferred offering costs is charged against equity. The capitalization table provides a coherent share-count bridge, unlike a conflicting narrative count.
• Future supply: Directors and executives face 365-day lock-ups; other holders and option holders face 180 days. The remaining 5,299,557 shares are generally restricted initially. Another 1,803,562 shares are reserved for future equity awards. Representative warrants cover 150,000 shares at 125% of the IPO price.

Key Financial Highlights

$M; losses and outflows in parentheses. “After IPO” assumes note conversion and the offering at $11.00, net of costs; operating results remain historical.

• Expense drivers: Stock-based compensation fell $0.442M in FY2025 and $0.663M in H1 2026. Interim R&D increased to $0.260M, principally because storage and shipping reached $0.159M; historical spending is not a guide to trial-stage costs.
• Cash conversion: FY2024 benefited from $0.667M of deferred collaboration receipts, explaining why FY2025 cash use worsened despite lower losses. H1 2026 cash use benefited from $0.254M of additional unpaid expenses.
• Negative equity: Accumulated losses of $17.7M—not preferred-stock accounting—drive the deficit. Much of the liability burden comprises unpaid expenses and interest rather than borrowing.

Governance and Control

• Common shares carry one vote each, but CEO Daniel Vlock retains 55.8% beneficial voting power. Alopexx qualifies as controlled but currently intends not to use controlled-company exemptions; its staggered board further limits outside influence.
• Insider financing has sustained operations. The IPO activates Vlock’s $0.525M annual salary. Outstanding management and director options represent 14% of fully diluted shares and have $9.88M intrinsic value at the $11.00 midpoint, versus $0.0794M of H1 stock-based compensation expense.

Risk Assessment

• Going concern and controls: The auditor flags financing uncertainty; limited accounting staffing and segregation of duties also produced a material weakness whose remediation is not assured.
• Clinical and regulatory proof: Laboratory killing does not establish protection, and regulators could require large field-efficacy trials instead of AV0328’s proposed surrogate-endpoint pathway.
• Financing: The IPO does not fund pivotal trials; unsuccessful fundraising could halt programs or materially dilute buyers.
• Manufacturing: Sole-source Glycosyn dependence and unproven commercial-scale supply could delay trials or approval.
• Patent protection: Licensed patents expire in 2025–2033 before extensions, earlier than owned applications, potentially weakening exclusivity before commercialization.
• Valuation and control: Buyers pay for unproven clinical outcomes while lacking power to redirect Vlock’s strategy.

What to Watch

• AV0328: Watch whether the planned older-adult study starts and regulators accept its immune-response endpoints; additional efficacy requirements would expand funding needs.
• F598: The agreed intensive-care trial must demonstrate fewer infections, not merely tolerability; another efficacy failure would undermine the lead antibody case.
• Funding: Later filings should show proceeds advancing trials within the stated runway, rather than further delays followed by another capital raise.